Results 51 to 60 of about 21,252 (207)
British Journal of Clinical Pharmacology, EarlyView.Pharmacogenomic (PGx) information has the potential to support the safe and effective use of medicines, yet there is uncertainty about how this information can be best communicated to patients. Summaries of product characteristics (SmPCs) and patient information leaflets (PILs) for all UK‐approved medicines with strong evidence supporting a PGx ...
Parth Narlawar +5 more
wiley +1 more source
Day-case management of chronic suppurative otitis media with cholesteatoma with canal wall down technique surgery: long-term follow-up [PDF]
, 2017 The overall number of day-case otologic surgery cases is increasing; however, there is limited experience about performing canal wall down tympanoplasty in patients with chronic suppurative otitis media with cholesteatoma in this setting.
GRASSO, MICHELE +4 more
core +2 more sources
British Journal of Clinical Pharmacology, EarlyView.Aim There is limited research describing rivaroxaban overdose. We aim to describe rivaroxaban overdose, coagulopathy and bleeding complications. Methods This is a prospective series of acute adult (>14 years) rivaroxaban overdose presentations >40 mg enrolled in the Australian Toxicology Monitoring study and presenting to three Australian clinical ...
Katherine Z. Isoardi +3 more
wiley +1 more source
Changes in prescribed medicines in older patients with multimorbidity and polypharmacy in general practice [PDF]
, 2018 Background: Treatment complexity rises in line with the number of drugs, single doses, and administration methods, thereby threatening patient adherence. Patients with multimorbidity often need flexible, individualised treatment regimens, but alterations
Buedingen, Fiona von +5 more
core +1 more source
Jurnal Manajemen dan Pelayanan Farmasi, 2017 Currently, the most effective therapeutic agent as a Stress Related Mucosal Disease (SRMD) prophylaxis therapy is the group of Proton Pump Inhibitor (PPI).
Dyah Atmi Tri Sukengtyas +2 more
doaj +1 more source
CYP2C19 Genotype is Associated with Citalopram Treatment Outcomes in a Real‐World Setting
Clinical Pharmacology &Therapeutics, EarlyView.CYP2C19 metabolizes various selective serotonin reuptake inhibitors (SSRIs) and genetic CYP2C19 variants are associated with SSRI tolerability and response. Yet, whether CYP2C19 variability also impacts citalopram response remained unclear. We here evaluated associations between CYP2C19 genotypes and citalopram prescription data of 11,079 patients from
Yoomi Park +2 more
wiley +1 more source
Management of Duodenal Ulcer with Gastroesophageal Reflux Disease (GERD) with Intravenous Pantoprazole [PDF]
, 2003 Proton pump inhibitors (PPIs) are the most effective anti secretory drugs available for controlling gastric acid acidity and volume. They are the drug of choice in the treatment for gastro esophageal reflux disease (GERD), Helicobacter pylori eradication,
Abdullah, M. (Murdani) +5 more
core
The Kaohsiung Journal of Medical Sciences, EarlyView.ABSTRACT Carotid artery stenting (CAS) is an effective treatment for carotid stenosis. Proton‐pump inhibitors (PPIs) are commonly prescribed in the general population. However, the impact of PPI use on outcomes following CAS remains unknown. This study investigated the impact of PPI use on CAS using a retrospective, matched‐cohort analysis from the ...
Chia‐En Wong +7 more
wiley +1 more source
Degradation of lansoprazole and omeprazole in the aquatic environment [PDF]
, 2006 Lansoprazole and omeprazole degrade in water leading to sulfides, benzimidazolones and a red complex material. Degradation is accelerated in acid medium and by solar simulator irradiation.
BRIGANTE M. +5 more
core +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background Microscopic colitis (MC) typically presents with chronic, non‐bloody watery diarrhea. Diagnosis requires endoscopy with colonic mucosal biopsies. The etiology is multifactorial, with several medications implicated, although only a few cases have been attributed to oral levodopa/dopa‐decarboxylase inhibitor (LDDCI) therapy.
Romana Hintner +10 more
wiley +1 more source